First Time Loading...

Gain Therapeutics Inc
NASDAQ:GANX

Watchlist Manager
Gain Therapeutics Inc Logo
Gain Therapeutics Inc
NASDAQ:GANX
Watchlist
Price: 2.92 USD 0.69% Market Closed
Updated: May 8, 2024
Section:
 

Wall Street
Price Targets

GANX Price Targets Summary
Gain Therapeutics Inc

Wall Street analysts forecast GANX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GANX is 8.98 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

GANX Lowest Forecast
Wall Street Target
6.06 USD
108% Upside
GANX Average Forecast
Wall Street Target
8.98 USD
207% Upside
GANX Highest Forecast
Wall Street Target
10.5 USD
260% Upside
Lowest
Price Target
6.06 USD
108% Upside
Average
Price Target
8.98 USD
207% Upside
Highest
Price Target
10.5 USD
260% Upside
Gain Therapeutics Inc Competitors:
Price Targets
BCYC
Bicycle Therapeutics PLC
87% Upside
603739
Qingdao Vland Biotech INC
28% Downside
N
NYKD
Nykode Therapeutics ASA
190% Upside
KYMR
Kymera Therapeutics Inc
36% Upside
BCYC
Bicycle Therapeutics PLC
87% Upside
603739
Qingdao Vland Biotech INC
28% Downside
N
NYKD
Nykode Therapeutics ASA
190% Upside
KYMR
Kymera Therapeutics Inc
36% Upside
KRON
Kronos Bio Inc
301% Upside
NGNE
Neurogene Inc
45% Upside
I
688382
InventisBio Co Ltd
66% Upside
4587
PeptiDream Inc
39% Upside

Revenue
Forecast

Revenue Estimate
Gain Therapeutics Inc

For the last 4 years the compound annual growth rate for Gain Therapeutics Inc's revenue is 8%. The projected CAGR for the next 3 years is 28%.

8%
Past Growth
28%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Gain Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Gain Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-29%
Average Miss
What are analyst estimates?

See Also

Summary
GANX intrinsic value, competitors valuation, and company profile.
DCF Valuation
GANX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GANX stock valuation using valuation multiples.
Wall Street Estimates
GANX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GANX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GANX's stock price target?
Price Target
8.98 USD

According to Wall Street analysts, the average 1-year price target for GANX is 8.98 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

What is Gain Therapeutics Inc's Revenue forecast?
Projected CAGR
28%

For the last 4 years the compound annual growth rate for Gain Therapeutics Inc's revenue is 8%. The projected CAGR for the next 3 years is 28%.

ALPHA SPREAD
Join more than 135,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.